Esperion therapeutics, inc. (ESPR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Revenues:
Total Revenues

1,840

982

1,000

1,000

145,419

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of goods sold

31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

34,702

38,234

48,281

42,788

46,308

49,473

41,551

39,524

40,940

33,439

40,056

38,248

35,860

24,881

13,498

9,698

9,791

7,956

7,247

7,209

7,390

6,200

7,174

6,528

5,400

7,338

3,483

3,100

2,093

1,654

2,456

2,330

1,557

Selling, general and administrative

41,553

21,712

18,468

13,492

12,182

11,176

9,011

6,956

5,954

5,257

5,681

5,412

5,029

4,404

4,214

4,633

5,031

5,278

5,672

5,253

4,035

3,180

2,526

2,726

2,490

2,398

1,924

1,172

1,251

505

533

533

632

Total operating expenses

76,286

59,946

66,749

56,280

58,490

60,649

50,562

46,480

46,894

38,696

45,737

43,660

40,889

29,285

17,712

14,331

14,822

13,234

12,919

12,462

11,425

9,380

9,700

9,254

7,890

9,736

5,407

4,272

3,344

2,160

2,990

2,863

2,189

Income (loss) from operations

-74,446

-58,964

-65,768

-55,298

86,929

-60,649

-50,562

-46,480

-46,894

-38,696

-45,737

-43,660

-40,889

-29,285

-17,712

-14,331

-14,822

-13,234

-12,919

-12,462

-11,425

-9,380

-9,700

-9,254

-7,890

-9,736

-5,407

-4,272

-3,344

-2,160

-2,990

-2,863

-2,189

Interest expense

4,171

4,124

3,996

-

-

-

-

-

-

-

-

-

-

78

89

99

110

121

130

135

134

134

135

1

-

0

0

108

828

561

361

303

260

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,545

42

-32

-

-

-

Other income, net

368

1,142

1,387

1,077

450

610

651

750

764

805

518

323

348

407

399

395

347

233

248

202

93

57

29

17

16

46

169

4

-25

-86

0

0

1

Net income (loss)

-78,249

-61,946

-68,377

-54,221

87,379

-60,039

-49,911

-45,730

-46,130

-37,891

-45,219

-43,337

-40,541

-28,956

-17,402

-14,035

-14,585

-13,122

-12,801

-12,395

-11,466

-9,457

-9,806

-9,238

-7,874

-9,690

-5,238

-6,921

-4,239

-2,775

-3,351

-3,166

-2,448

Net income (loss) per common share - basic

-2.84

-

-

-2.01

3.26

-

-

-1.71

-1.73

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share - diluted

-2.84

-

-

-2.01

3.07

-

-

-1.71

-1.73

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding - basic

27,519

-

-

26,968

26,842

-

-

26,786

26,605

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding - diluted

27,519

-

-

26,968

28,449

-

-

26,786

26,605

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per common share (basic and diluted)

-

-

-2.52

-

-

-2.24

-1.86

-

-

-1.44

-1.86

-1.92

-1.80

-1.29

-0.77

-0.62

-0.65

-0.58

-0.57

-0.55

-0.56

-0.49

-0.64

-0.60

-0.51

29.09

-0.34

-19.82

-12.24

-8.12

-10.31

-9.94

-7.96

Weighted-average shares outstanding (basic and diluted)

-

-

27,171

-

-

26,818

26,804

-

-

26,222

24,311

22,591

22,563

22,554

22,550

22,541

22,532

22,515

22,494

22,465

20,589

19,276

15,432

15,399

15,369

15,594

15,253

349

346

341

325

318

307

Other comprehensive income (loss):
Unrealized gain (loss) on investments

-14

12

27

95

208

241

216

187

-118

-

-

-

-

-

-

-

-

-

-

-

-

-54

3

-8

3

-

6

-

-

-

-

-

-

Comprehensive income (loss)

-78,263

-61,934

-68,350

-54,126

87,587

-59,798

-49,695

-45,543

-46,248

-

-

-

-

-

-

-

-

-

-

-

-

-9,511

-9,803

-9,246

-7,871

-

-5,232

-

-

-

-

-

-

Product sales, net
Total Revenues

900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total Revenues

982

-

-

-

145,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-